PMID: 26788735Jan 21, 2016Paper

Meningococcal B vaccine and the vision of a meningitis free world

Journal of Preventive Medicine and Hygiene
A BianchiA Prugnola

Abstract

A century of traditional vaccinology lost the fight against meningococcus serogroup B (MenB). However, thanks to an innovative genome-based approach, the first broadly effective MenB vaccine, Bexsero® (GSK Vaccines), was developed and has been licensed for use in various age groups by the European Commission and other regulatory authorities. Genes encoding for the main meningococcus B antigens were identified and screened in order to achieve a broadly protective vaccine, taking into account the fact that meningococcus B has many different subtypes whose membrane proteins may be different. Since the antigens selected for Bexsero® are also harbored by meningococci belonging to other serogroups there may be the potential for Bexsero® to offer a certain level of protection against non-B serogroups. Therefore preliminary studies were carried out to investigate the potential of the vaccine to also provide a degree of cross protection against non-B serogroups. Here we review the potential for Bexsero® to offer a certain level of protection against the diversity of meningococcus type B subtypes and its potential ability to offer some cross protection from non-B serogroups. Lastly, we describe the future perspectives in pentavalent meni...Continue Reading

Related Concepts

Related Feeds

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Related Papers

Pathogens and Global Health
George Vernikos, Duccio Medini
Igiene e sanità pubblica
Cristiana CarlinoElisabetta Franco
© 2022 Meta ULC. All rights reserved